As of now, most prescriptions are issued for obesity management, with a smaller percentage for diabetes
Tirzepatides dual action sets it apart from medications like semaglutide (Wegovy or Ozempic): GLP-1 activity Increases the number of pancreatic betal cells Stimulates insulin secretion by beta cells Increases insulin sensitivity Increases clearance of triglycerides (a type of cholesterol) Breaks up fats Delays stomach emptying Acts on the brains appetite centers to promote fullness GIP activity Mainly acts on pancreas Decreases glucagon release by the pancreas Increases insulin release Promotes fat storage Supports the synthesis of glycogen People with type 2 diabetes often have abnormally low levels of GIP, or their pancreatic cells do not respond normally to GIP to release an adequate amount of insulin with food intake
Preliminary data presented at the recent 85th Scientific Sessions of the American Diabetes Association showed that semaglutide 7.2 mg achieved a mean weight loss of 21%, outperforming the 2.4 mg dose
Research shows that the majority of people who lose weight eventually regain it but that doesnt have to be the case
Clinical experience suggests these patients should start preventive acid-suppressing medication (usually a PPI) at the same time they begin semaglutide, rather than waiting for symptoms to develop
If you experience nausea, temporarily reducing rice portions or choosing very plain preparations may help until symptoms subside